Antagonist activity at Sprague-Dawley rat ETA receptor assessed as inhibition of ET1-induced contraction of thoracic aortic ring at 10 uM after 30 mins
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated right ventricular systolic pressure at 20 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated right ventricular systolic pressure at 40 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated right ventricular systolic pressure at 80 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced central vein pressure at 20 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced central vein pressure at 40 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced central vein pressure at 80 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in po dosed Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated right ventricular systolic pressure administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in po dosed Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced central vein pressure administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/BW at 20 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/BW at 40 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/BW at 80 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/(LV+S) at 20 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/(LV+S) at 40 mg/kg, po administered for 28 days measured on day 29 relative to untreated control
Antihypertensive activity in Sprague-Dawley rat PAH model assessed as reduction in hypoxia-induced elevated RV/(LV+S) at 80 mg/kg, po administered for 28 days measured on day 29 relative to untreated control